FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303336> ?p ?o ?g. }

• W4367303336 abstract "<h3>Objective:</h3> To determine if extended interval dosing (EID) of ocrelizumab is associated with changes in disease activity in patients with multiple sclerosis (MS). <h3>Background:</h3> During the COVID-19 pandemic, EID of ocrelizumab (standard interval dosing (SID)= every 6 months) was employed variably by neurologists at our center due to concerns about COVID-19 risk or reduced COVID-19 vaccine efficacy. This time period provides the opportunity to evaluate whether EID is associated with greater risk of breakthrough MS activity. <h3>Design/Methods:</h3> Medical records of patients at our institution who were on ocrelizumab treatment as of March 2020 were reviewed. Demographic, clinical, and imaging data and infusion dates were collected. EID was defined as ≥ 8 months in the primary analysis and ≥ 12 months in secondary analyses. <h3>Results:</h3> Overall, 364 patients, 275 (75.5%) with relapsing-remitting MS (RRMS) and 89 (24.5%) with progressive MS (PMS), were included (mean age 42.4±10.9 years; 72% females). They received ocrelizumab for an average of 38.2±14.9 months; and infusion intervals ranged from 4 to 32 months. 190 patients (52.4% of RRMS and 51.6% of PMS) had at least one EID ≥ 8 months, while 89 patients (21% of RRMS and 18% of PMS) had at least one EID ≥ 12 months. There was no difference in sex, age, or MS type between EID and SID groups. Reasons for EID (≥ 8 months) included COVID concerns (58%), infections (8%), pregnancy (8%), or other (26%). Only 1 EID and 1 SID patient had a clinical relapse. Among 258 RRMS patients who had re-baseline MRI after starting ocrelizumab, 3 (2.2%) EID patients (≥ 8 months) had new lesions on imaging vs none in those with SID. No participant with PMS had breakthrough MRI activity. <h3>Conclusions:</h3> Results suggest no marked risk of inflammatory MS activity associated with EID for ocrelizumab when compared to SID. <b>Disclosure:</b> Dr. Bou Rjeily has nothing to disclose. The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society. Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Mowry has received research support from Biogen. The institution of Dr. Mowry has received research support from Teva. The institution of Dr. Mowry has received research support from Genzyme. The institution of Dr. Mowry has received research support from Genentech." @default.
• W4367303336 created "2023-04-29" @default.
• W4367303336 creator A5010022210 @default.
• W4367303336 creator A5023506438 @default.
• W4367303336 creator A5026263678 @default.
• W4367303336 date "2023-04-25" @default.
• W4367303336 modified "2023-10-18" @default.
• W4367303336 title "Extended Interval Dosing of Ocrelizumab in Patients with Multiple Sclerosis Is Not Associated with Meaningful Differences in Disease Activity (P14-3.010)" @default.
• W4367303336 doi "https://doi.org/10.1212/wnl.0000000000204024" @default.
• W4367303336 hasPublicationYear "2023" @default.
• W4367303336 type Work @default.
• W4367303336 citedByCount "0" @default.
• W4367303336 crossrefType "proceedings-article" @default.
• W4367303336 hasAuthorship W4367303336A5010022210 @default.
• W4367303336 hasAuthorship W4367303336A5023506438 @default.
• W4367303336 hasAuthorship W4367303336A5026263678 @default.
• W4367303336 hasConcept C126322002 @default.
• W4367303336 hasConcept C187212893 @default.
• W4367303336 hasConcept C195910791 @default.
• W4367303336 hasConcept C203014093 @default.
• W4367303336 hasConcept C2777288759 @default.
• W4367303336 hasConcept C2778843634 @default.
• W4367303336 hasConcept C2779134260 @default.
• W4367303336 hasConcept C2779338263 @default.
• W4367303336 hasConcept C2780640218 @default.
• W4367303336 hasConcept C2780653079 @default.
• W4367303336 hasConcept C3008058167 @default.
• W4367303336 hasConcept C44249647 @default.
• W4367303336 hasConcept C524204448 @default.
• W4367303336 hasConcept C71924100 @default.
• W4367303336 hasConceptScore W4367303336C126322002 @default.
• W4367303336 hasConceptScore W4367303336C187212893 @default.
• W4367303336 hasConceptScore W4367303336C195910791 @default.
• W4367303336 hasConceptScore W4367303336C203014093 @default.
• W4367303336 hasConceptScore W4367303336C2777288759 @default.
• W4367303336 hasConceptScore W4367303336C2778843634 @default.
• W4367303336 hasConceptScore W4367303336C2779134260 @default.
• W4367303336 hasConceptScore W4367303336C2779338263 @default.
• W4367303336 hasConceptScore W4367303336C2780640218 @default.
• W4367303336 hasConceptScore W4367303336C2780653079 @default.
• W4367303336 hasConceptScore W4367303336C3008058167 @default.
• W4367303336 hasConceptScore W4367303336C44249647 @default.
• W4367303336 hasConceptScore W4367303336C524204448 @default.
• W4367303336 hasConceptScore W4367303336C71924100 @default.
• W4367303336 hasLocation W43673033361 @default.
• W4367303336 hasOpenAccess W4367303336 @default.
• W4367303336 hasPrimaryLocation W43673033361 @default.
• W4367303336 hasRelatedWork W2151847718 @default.
• W4367303336 hasRelatedWork W2272446420 @default.
• W4367303336 hasRelatedWork W2765814236 @default.
• W4367303336 hasRelatedWork W2956548199 @default.
• W4367303336 hasRelatedWork W2997394796 @default.
• W4367303336 hasRelatedWork W3010644420 @default.
• W4367303336 hasRelatedWork W3034725616 @default.
• W4367303336 hasRelatedWork W3036083494 @default.
• W4367303336 hasRelatedWork W3182459058 @default.
• W4367303336 hasRelatedWork W3206414309 @default.
• W4367303336 isParatext "false" @default.
• W4367303336 isRetracted "false" @default.
• W4367303336 workType "article" @default.